Kosuke Kashiwabara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8666861/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer, 2017, 6, 325-336.	4.2	202
2	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 791-803.	0.5	127
3	Liver Resection for Multiple Hepatocellular Carcinomas. Annals of Surgery, 2020, 272, 145-154.	2.1	61
4	Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. Diseases of the Colon and Rectum, 2018, 61, 803-808.	0.7	36
5	Spread through air spaces is an independent predictor of recurrence in stage III (N2) lung adenocarcinoma. Interactive Cardiovascular and Thoracic Surgery, 2019, 29, 442-448.	0.5	28
6	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer, 2019, 8, 403-411.	4.2	28
7	High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. Journal of Thoracic Disease, 2018, 10, 4741-4750.	0.6	20
8	Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. Journal of Cancer, 2017, 8, 4057-4064.	1.2	15
9	Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. Diseases of the Colon and Rectum, 2018, 61, 461-471.	0.7	12
10	Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial. Japanese Journal of Clinical Oncology, 2016, 46, 879-882.	0.6	10
11	Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. Oncologist, 2020, 25, e223-e230.	1.9	10
12	Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast, 2021, 55, 63-68.	0.9	9
13	Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD) Journal of Clinical Oncology, 2019, 37, 1070-1070.	0.8	8
14	Incidence of and risk factors for selfâ€loadâ€related and medical deviceâ€related pressure injuries in critically ill patients: A prospective observational cohort study. Wound Repair and Regeneration, 2022, 30, 453-467.	1.5	7
15	Competing Risk Analysis in Lung Cancer Patients Over 80 Years Old Undergoing Surgery. World Journal of Surgery, 2019, 43, 1857-1866.	0.8	6
16	Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials. Oncotarget, 2017, 8, 99150-99160.	0.8	5
17	Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). International Journal of Cardiovascular Imaging, 2017, 33, 779-787.	0.7	4
18	Impact of Residual Stenosis on the Angiographic Edge Restenosis of a Second-Generation Drug-Eluting Stent. International Heart Journal, 2019, 60, 1050-1060.	0.5	4

#	Article	IF	CITATIONS
19	Associated factors for and progression rate of sacroiliac joint degeneration in subjects undergoing comprehensive medical checkups. European Spine Journal, 2020, 29, 579-585.	1.0	4
20	Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC. BMC Cancer, 2021, 21, 34.	1.1	3
21	Risk factors associated with recurrence by peritoneal dissemination or paraaortic lymph node metastasis after curative surgery in patients with colorectal cancer. Annals of Cancer Research and Therapy, 2016, 24, 58-59.	0.1	2
22	Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. BMJ Open, 2021, 11, e048354.	0.8	2
23	A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events. Therapeutic Innovation and Regulatory Science, 2014, 48, 444-452.	0.8	1
24	Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors. Japanese Journal of Clinical Oncology, 2018, 48, 248-254.	0.6	1
25	Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Breast Cancer, 2022, 29, 131-143.	1.3	1
26	Pineal cyst: results of long-term MRI surveillance and analysis of growth and shrinkage rates. Journal of Neurosurgery, 2022, , 1-7.	0.9	1
27	Reasonable twoâ€stage adaptive designs for singleâ€arm phase II clinical trials. Pharmaceutical Statistics, 2018, 17, 770-780.	0.7	0
28	Hazard rate of tumor recurrence over time: a pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC). Annals of Cancer Research and Therapy, 2016, 24, 60-61.	0.1	0
29	Prognostic Nomogram for Colorectal Cancer after Radical Resection in Japanese population. Annals of Cancer Research and Therapy, 2016, 24, 56-57.	0.1	0
30	Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. Biomarkers in Medicine, 2022, , .	0.6	0